The present invention relates to a transdermal therapeutic system formed from (a) a backing layer, (b) a solvent-based self-adhesive matrix layer containing rotigotine as active ingredient, and (c) a release liner, in which the self-adhesive matrix layer has a coating weight of about 75-400 g/m.sup.2 and comprises a reservoir layer containing about 9-25 wt.-% rotigotine based on the weight of the reservoir layer; a kit containing two transdermal therapeutic systems of the present invention; and methods for the preparation of the transdermal therapeutic system of the present invention. The present invention further relates to methods of treatment based upon the application of the inventive transdermal therapeutic systems once or twice weekly via systems adapted to allow for the transdermal administration of therapeutically effective amounts of rotigotine for at least 3 days.

A hydrophilic active molecule delivery system whereby active molecules can be released on demand and/or a variety of different active molecules can be delivered from the same system and/or different concentrations of active molecules can be delivered from the same system. The system may be used to deliver/release hydrophilic active molecules that are incompatible to each other.

A benefit agent delivery system whereby benefit agents can be released over a period of time and/or a variety of different benefit agents can be delivered from the same system and/or different concentrations of benefit agents can be delivered from the same system. The benefit agent delivery system includes a plurality of microcells, wherein the microcells are filled with a formulation comprising a benefit agent and an organic solvent. The microcells include an opening, and the opening is spanned by a porous diffusion layer. Different microcells may be loaded with different benefit agents, thereby providing a mechanism to deliver different, complimentary, or incompatible benefit agents.

The present invention relates to transdermal therapeutic systems for the transdermal administration of rotigotine containing a therapeutically effective amount of rotigotine base in a self-adhesive layer structure that includes a backing layer and a rotigotine-containing biphasic layer. The biphasic layer has an outer phase formed from a polymer or a polymer mixture along with an inner phase that includes rotigotine base and a polymer mixture including polyvinylpyrrolidone having a K-Value of at least 80 and at least one further hydrophilic polymer selected from the polymer groups: copolymers of vinyl caprolactam, vinylacetate and ethylene glycol, copolymers of vinylpyrrolidone and vinylacetate, copolymers of ethylene and vinylacetate, polyethylene glycols, polypropylene glycols, acrylic polymers, and modified celluloses. The inner phase forms dispersed deposits in the outer phase. The inventive transdermal therapeutic systems optionally include a skin contact layer.

Carefully coordinated patches having camouflaging and/or benefit properties can be formed for application to a desired region of human skin. The patches include a flexible film having a first, adhesive, outwardly facing major surface and a second outwardly facing surface which is textured to correspond to skin covered by the patch during use; wherein the flexible film further comprises at least one pigmented region and at least one region adapted to modify one or more optical properties selected from the group consisting of light transmission, light reflection, and light absorption. Methods of custom use of such patches may include 3D printing processes.

Provided are devices, i.e. medical devices, for topical delivery of various active agents to a target site. More specifically, provided are devices for controlled release of an active agent to a skin portion upon contact with an aqueous fluid, such as perspiration, exudate or external applied water-based fluids.

The present invention relates to a multilayer composite material for the treatment of wounds and lesions and to a dressing comprising said multilayer material.

Stretchable, occlusive backing layers for transdermal drug delivery systems are disclosed, that maintain occlusivity after stretching. The backing layers are comprised of a stretchable backing material provided with an occlusive coating comprising a styrene-isoprene-styrene block copolymer and tackifier. Also described are transdermal drug delivery systems having such backing layers, including transdermal drug delivery systems for non-steroidal anti-inflammatory drugs (NSAIDs), and methods of making and using such backing layers and transdermal drug delivery systems.

A transdermal delivery system for systemic delivery of donepezil is described, where the system comprises an adhesive matrix drug reservoir layer comprised of a copolymer of acrylic acid/vinyl acetate, triethyl citrate, and donepezil base generated in situ by reaction of donepezil HCl and an alkaline salt. The system is provided for treatment of Alzheimer's disease, and achieves transdermal delivery of the therapeutic agent at steady state that is bioequivalent to administration of the therapeutic agent orally.

The present invention provides an aqueous patch which can stably contain only one of an S-enantiomer and an R-enantiomer of a drug capable of being present in such enantiomers at a relatively high concentration over a long period of time, has the excellent adhesive property and the excellent shape retaining property, and achieves high skin permeability of the drug. Specifically, the present invention provides an aqueous patch containing only one of enantiomers of a drug as an active ingredient in a pasty preparation.